CEPI & AVAREF Boost Clinical Trial Reviews in Africa
- A new partnership between the Coalition for Epidemic Preparedness Innovations (CEPI) and the African Vaccine Regulatory Forum (AVAREF) aims to substantially reduce the time it takes to review...
- Historically, the process of gaining regulatory approval for clinical trials in Africa has been lengthy and complex.
- The Impact of Delays: Every month lost in clinical trial approval translates to increased risk and potential spread of infectious diseases.
Accelerating Vaccine Growth: CEPI and AVAREF Partner to Streamline Clinical Trial Reviews in Africa
Table of Contents
A new partnership between the Coalition for Epidemic Preparedness Innovations (CEPI) and the African Vaccine Regulatory Forum (AVAREF) aims to substantially reduce the time it takes to review and approve clinical trial applications for vaccines across the African continent.Announced on October 7, 2025, this collaboration addresses a critical bottleneck in rapidly responding to future pandemic threats.
The Challenge: Slow Clinical Trial Approvals
Historically, the process of gaining regulatory approval for clinical trials in Africa has been lengthy and complex. This is due to a number of factors, including varying regulatory requirements across different countries and a lack of harmonized review processes. These delays can hinder the swift evaluation of potential vaccines during outbreaks, potentially costing lives and prolonging epidemics.
How the CEPI-AVAREF Partnership Will Work
The partnership will focus on strengthening the capacity of regulatory agencies in Africa to efficiently and effectively review clinical trial applications. CEPI will provide financial and technical support to AVAREF,enabling it to expand its network of regulatory experts and enhance its review processes. This includes investing in training programs and providing access to cutting-edge tools and technologies.
AVAREF, established in 2019 by the African Union Development Agency-NEPAD (NEPAD), serves as a platform for regulatory harmonization and collaboration across the continent. By leveraging AVAREF’s existing infrastructure and expertise, the partnership aims to create a more streamlined and predictable regulatory landscape for vaccine development.
Key Benefits of a Faster Review Process
- Rapid Response to Outbreaks: Quicker approvals mean vaccines can be tested and deployed more rapidly during outbreaks, potentially saving lives and mitigating the impact of epidemics.
- Increased Investment in African Research: A more efficient regulatory environment can attract increased investment in vaccine research and development within Africa.
- Strengthened Local Capacity: The partnership will contribute to building a stronger and more resilient public health system in Africa.
- Equitable Access to Vaccines: faster clinical trials can accelerate the availability of vaccines to populations in need.
The Broader Context: Global Health Security
This initiative is part of a broader global effort to strengthen pandemic preparedness and response. The COVID-19 pandemic highlighted the critical need for faster vaccine development and equitable access to vaccines worldwide. CEPI, founded in 2017, plays a central role in this effort by investing in the development of vaccines against emerging infectious diseases.
Investing in regulatory capacity is just as important as investing in vaccine research and development. A strong regulatory system is essential for ensuring the safety and efficacy of vaccines and for accelerating their availability to those who need them most.
Looking Ahead
The CEPI-AVAREF partnership represents a significant step forward in strengthening Africa’s capacity to respond to future pandemic threats. By streamlining clinical trial reviews and fostering collaboration among regulatory agencies, this initiative will help ensure that life-saving vaccines are developed and deployed more quickly and efficiently across the continent. The initial focus will be on supporting clinical trials for priority diseases, with the potential to expand to other areas in the future.
